This Pennsylvania, USA small startup pharmaceutical company is developing a new treatment for treating osteoarthritis (OA). It is poised to be the first disease-modifying product on the market, relieves pain, and increases function. The company founders and principals are seasoned pharmaceutical executives, entrepreneurs, and scientists with decades of drug development experience.
OA is a leading cause of disability in persons over 60 years of age. It is characterized by chronic pain and stiffness in the joints, particularly the knee, hip, back, shoulder and hands.